vs
Side-by-side financial comparison of ARTIVION, INC. (AORT) and OLD SECOND BANCORP INC (OSBC). Click either name above to swap in a different company.
ARTIVION, INC. is the larger business by last-quarter revenue ($116.0M vs $93.8M, roughly 1.2× OLD SECOND BANCORP INC). OLD SECOND BANCORP INC runs the higher net margin — 27.3% vs 2.1%, a 25.2% gap on every dollar of revenue. Over the past eight quarters, OLD SECOND BANCORP INC's revenue compounded faster (15.1% CAGR vs 9.1%).
Artivion, Inc. is a distributor of cryogenically preserved human tissues for cardiac and vascular transplant applications and develops medical devices. Among its products are human heart valves, which are treated to remove excess cellular material and antigens, and BioGlue surgical adhesive.
U.S. Bancorp is an American multinational banking institution headquartered in Minneapolis, Minnesota and incorporated in Delaware. It is the 5th-largest bank in the United States as of 2025. As the largest bank in the Midwestern United States, it is considered systemically important by the Financial Stability Board. It is the parent company of its primary operating entity, U.S. Bank National Association, which does business as U.S. Bank. The company provides banking, investment, mortgage, tr...
AORT vs OSBC — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $116.0M | $93.8M |
| Net Profit | $2.4M | $25.6M |
| Gross Margin | 63.1% | — |
| Operating Margin | 9.2% | — |
| Net Margin | 2.1% | 27.3% |
| Revenue YoY | 19.2% | — |
| Net Profit YoY | 114.7% | 159.2% |
| EPS (diluted) | $0.06 | $0.48 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $93.8M | ||
| Q4 25 | $116.0M | $95.2M | ||
| Q3 25 | $113.4M | $95.9M | ||
| Q2 25 | $113.0M | $75.1M | ||
| Q1 25 | $99.0M | $73.1M | ||
| Q4 24 | $97.3M | $73.2M | ||
| Q3 24 | $95.8M | $71.2M | ||
| Q2 24 | $98.0M | $70.8M |
| Q1 26 | — | $25.6M | ||
| Q4 25 | $2.4M | — | ||
| Q3 25 | $6.5M | $9.9M | ||
| Q2 25 | $1.3M | $21.8M | ||
| Q1 25 | $-505.0K | $19.8M | ||
| Q4 24 | $-16.5M | — | ||
| Q3 24 | $-2.3M | $23.0M | ||
| Q2 24 | $-2.1M | $21.9M |
| Q1 26 | — | — | ||
| Q4 25 | 63.1% | — | ||
| Q3 25 | 65.6% | — | ||
| Q2 25 | 64.7% | — | ||
| Q1 25 | 64.2% | — | ||
| Q4 24 | 63.2% | — | ||
| Q3 24 | 63.7% | — | ||
| Q2 24 | 64.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | 9.2% | 41.2% | ||
| Q3 25 | 11.1% | 13.6% | ||
| Q2 25 | 7.4% | 38.9% | ||
| Q1 25 | 2.2% | 35.8% | ||
| Q4 24 | 2.7% | 34.7% | ||
| Q3 24 | 4.6% | 41.9% | ||
| Q2 24 | 6.6% | 41.2% |
| Q1 26 | — | 27.3% | ||
| Q4 25 | 2.1% | — | ||
| Q3 25 | 5.7% | 10.3% | ||
| Q2 25 | 1.2% | 29.0% | ||
| Q1 25 | -0.5% | 27.1% | ||
| Q4 24 | -16.9% | — | ||
| Q3 24 | -2.4% | 32.3% | ||
| Q2 24 | -2.2% | 30.9% |
| Q1 26 | — | $0.48 | ||
| Q4 25 | $0.06 | $0.53 | ||
| Q3 25 | $0.13 | $0.18 | ||
| Q2 25 | $0.03 | $0.48 | ||
| Q1 25 | $-0.01 | $0.43 | ||
| Q4 24 | $-0.40 | $0.42 | ||
| Q3 24 | $-0.05 | $0.50 | ||
| Q2 24 | $-0.05 | $0.48 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $64.9M | $115.7M |
| Total DebtLower is stronger | $215.1M | — |
| Stockholders' EquityBook value | $448.2M | $893.3M |
| Total Assets | $884.8M | $6.8B |
| Debt / EquityLower = less leverage | 0.48× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $115.7M | ||
| Q4 25 | $64.9M | $124.0M | ||
| Q3 25 | $73.4M | $116.5M | ||
| Q2 25 | $53.5M | $141.8M | ||
| Q1 25 | $37.7M | $256.1M | ||
| Q4 24 | $53.5M | $99.3M | ||
| Q3 24 | $56.2M | $115.8M | ||
| Q2 24 | $55.0M | $120.9M |
| Q1 26 | — | — | ||
| Q4 25 | $215.1M | — | ||
| Q3 25 | $214.9M | — | ||
| Q2 25 | $215.6M | — | ||
| Q1 25 | $314.7M | — | ||
| Q4 24 | $314.3M | — | ||
| Q3 24 | $314.0M | — | ||
| Q2 24 | $313.6M | — |
| Q1 26 | — | $893.3M | ||
| Q4 25 | $448.2M | $896.8M | ||
| Q3 25 | $438.7M | $866.7M | ||
| Q2 25 | $419.9M | $718.6M | ||
| Q1 25 | $294.3M | $694.5M | ||
| Q4 24 | $276.2M | $671.0M | ||
| Q3 24 | $304.7M | $661.4M | ||
| Q2 24 | $295.1M | $619.3M |
| Q1 26 | — | $6.8B | ||
| Q4 25 | $884.8M | $6.9B | ||
| Q3 25 | $857.7M | $7.0B | ||
| Q2 25 | $838.4M | $5.7B | ||
| Q1 25 | $791.2M | $5.7B | ||
| Q4 24 | $789.1M | $5.6B | ||
| Q3 24 | $803.1M | $5.7B | ||
| Q2 24 | $789.5M | $5.7B |
| Q1 26 | — | — | ||
| Q4 25 | 0.48× | — | ||
| Q3 25 | 0.49× | — | ||
| Q2 25 | 0.51× | — | ||
| Q1 25 | 1.07× | — | ||
| Q4 24 | 1.14× | — | ||
| Q3 24 | 1.03× | — | ||
| Q2 24 | 1.06× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $19.6M | — |
| Free Cash FlowOCF − Capex | $-7.9M | — |
| FCF MarginFCF / Revenue | -6.9% | — |
| Capex IntensityCapex / Revenue | 23.7% | — |
| Cash ConversionOCF / Net Profit | 8.06× | — |
| TTM Free Cash FlowTrailing 4 quarters | $839.0K | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $19.6M | $122.3M | ||
| Q3 25 | $22.3M | $35.9M | ||
| Q2 25 | $15.0M | $24.2M | ||
| Q1 25 | $-17.0M | $17.8M | ||
| Q4 24 | $10.1M | $131.5M | ||
| Q3 24 | $11.5M | $48.5M | ||
| Q2 24 | $6.1M | $11.6M |
| Q1 26 | — | — | ||
| Q4 25 | $-7.9M | $117.8M | ||
| Q3 25 | $17.7M | $34.7M | ||
| Q2 25 | $11.7M | $23.5M | ||
| Q1 25 | $-20.6M | $16.2M | ||
| Q4 24 | $8.7M | $120.7M | ||
| Q3 24 | $7.8M | $46.2M | ||
| Q2 24 | $3.6M | $8.7M |
| Q1 26 | — | — | ||
| Q4 25 | -6.9% | 123.7% | ||
| Q3 25 | 15.6% | 36.2% | ||
| Q2 25 | 10.4% | 31.2% | ||
| Q1 25 | -20.8% | 22.2% | ||
| Q4 24 | 9.0% | 165.0% | ||
| Q3 24 | 8.2% | 64.9% | ||
| Q2 24 | 3.7% | 12.3% |
| Q1 26 | — | — | ||
| Q4 25 | 23.7% | 4.7% | ||
| Q3 25 | 4.1% | 1.3% | ||
| Q2 25 | 2.9% | 1.1% | ||
| Q1 25 | 3.7% | 2.2% | ||
| Q4 24 | 1.5% | 14.7% | ||
| Q3 24 | 3.8% | 3.3% | ||
| Q2 24 | 2.6% | 4.2% |
| Q1 26 | — | — | ||
| Q4 25 | 8.06× | — | ||
| Q3 25 | 3.42× | 3.64× | ||
| Q2 25 | 11.16× | 1.11× | ||
| Q1 25 | — | 0.90× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 2.11× | ||
| Q2 24 | — | 0.53× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AORT
| Aortic Stent Grafts | $43.3M | 37% |
| On X | $27.8M | 24% |
| Preservation Services | $24.1M | 21% |
| Surgical Sealants | $20.3M | 18% |
| Other Products | $463.0K | 0% |
OSBC
| Net Interest Income | $81.1M | 87% |
| Noninterest Income | $12.6M | 13% |
